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Abstract. Aim: α-Hexylcinnamaldehyde (HCA), a compound
derived from cinnamaldehyde, was evaluated for its potential
chemosensitizing properties. Materials and Methods: The
cytotoxicity of HCA was tested against Caco-2, CCRF/CEM
and CEM/ADR5000 human cancer cells. Furthermore, its
ability to increase doxorubicin cytotoxicity was evaluated in
combination assays. Rhodamine123 efflux assay was carried
out in order to highlight the possible interference of HCA
with functionality of ATP-binding cassette (ABC)-
transporters. Results: In spite of a low cytotoxicity, HCA
increased the antiproliferative effect of doxorubicin in all the
cell lines tested, being particularly effective in CCRF/CEM.
The compound also reduced the rhodamine123 efflux in
Caco-2 and CEM/ADR5000 cells, suggesting a possible
interference with ABC transporter functionality. Conclusion:
Considering that the greatest synergism between HCA and
DOX was found against CCRF/CEM cells (lacking ABC
pumps), it seems likely that non-specific mechanisms,
including the alteration of membrane permeability, could be
involved in the chemosensitizing effect of HCA.
Chemotherapy with cytotoxic drugs represents the treatment of
choice for patients diagnosed with locally advanced and
metastatic cancer. Unfortunately, many oncological patients
often became insensitive to a variety of structurally and
mechanistically related and unrelated antitumor drugs, due to
the development of multidrug resistance (MDR). MDR is
defined as a multifactorial phenomenon in which both cellular
(due to the alterations of the malignant cell biochemistry) and
non-cellular mechanisms have been included (1). The first can
be classified into non-classical and transport-based classical
MDR phenotypes. Non-classical MDR mechanisms include
interference with the activity of some enzymes (e.g. glutathione
S-transferase and topoisomerase) that can reduce chemotherapy
efficacy, and changes in the balance of proteins involved in
apoptosis. Conversely, transport-based classical MDR
mechanisms are related to the ATP-binding cassette (ABC)-
transporter function (1), among which P-glycoprotein (MDR1;
encoded by ABCB1), multidrug resistance protein (MRP1;
encoded by ABCC1), and breast cancer resistance protein
(BCRP; encoded by ABCG2) have been most extensively
studied (1). These proteins are responsible for drug efflux from
cells, so their overexpression in cancer cells can reduce
anticancer drug bioavailability and favor MDR development.
In this context, inhibiting ABC transporter function (or 
their expression) by weakly cytotoxic agents (namely
chemosensitizers) represents a promising approach for MDR-
reversion and chemotherapy success. Furthermore, in
combination with a chemosensitizer, lower doses of anticancer
drugs are effective, hence the adverse effects of chemotherapy
can be reduced (2). In spite of their promising properties,
current MDR-reversal agents (e.g. verapamil) are only weakly
effective in vivo or produce too severe side-effects; therefore,
new bioactive compounds are still needed (3).
Cinnamaldehyde (cinnamic aldehyde, or 3-phenyl-2-
propenal), the major component (60-75%) of cinnamon bark
(Cinnamomum spp., Lauraceae) essential oil, has been found
to possess beneficial properties (including antimutagenic,
antioxidative, anti-inflammatory, and antiproliferative) and
has been shown to inhibit the MRP1 transporter (4, 5). In
spite of these activities, the clinical application of
cinnamaldehyde is limited due to its poor chemical stability
and rapid clearance (half-life of about 4 min) (6). Therefore,
some alkyl-derivatives have been developed in order to make
the molecule less reactive and more stable. In the present
study, the semisynthetic derivative α-hexylcinnamaldehyde
(HCA; Figure 1), widely used as an additive in food,
cosmetic and pharmaceutical industries (4), was investigated
for its chemosensitizing properties in human cancer cells.
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Materials and Methods
Cell lines. Human colorectal adenocarcinoma Caco-2 and T-cell
leukemia CCRF/CEM (Leibniz Institute DSMZ-German Collection
of Microorganisms and Cell Cultures, Braunschweig, Germany) and
CEM/ADR5000 cells (a MDR1-overexpressing and doxorubicin-
resistant leukemia subline kindly provided by Professor Thomas
Efferth, German Cancer Research Center, Heidelberg) were used
and cultivated according to El-Readi et al. (7). 
Cytotoxicity. Cell viability was evaluated by the 3-[4,5-
dimethylthiazol-2-yl] -2,5-diphenyl tetrazolium bromide (MTT)
assay (7) and determined as follow:
Viability (%)=[(ODtreated cells−ODmedium control)/
(ODuntreated cells−ODmedium control)]×100.
Combination assay. Cytotoxicity of doxorubicin (0.00005-1,000
μM) was tested, by MTT assay, in the presence of HCA, at
inhibitory concentrations (IC) which induce 10% (IC10) and 20%
(IC20) cytotoxicity, as found by the dose–response curve. The type
of interaction (synergistic, additive or antagonistic) was evaluated
by combination index (CI), isobologram analysis (IB), median-
effect equation (r-value), and reversal ratio value (RR) (4, 8).
Rhodamine 123 efflux assay. Rhodamine 123 (Rho123) is a
fluorescent dye effluxed by P-gp and MRP pumps, and is
accumulated in cells in the presence of ABC transporter inhibitor.
This assay was carried out according to El-Readi et al. (7) using
verapamil (20 μM) as a standard P-gp and MRP1 inhibitor (9). 
Statistical analysis. GraphPad Prism™ (Version 4.00) software
(GraphPad Software, Inc., San Diego, CA, USA) was used. All data
are expressed as the mean±standard error of the mean. Each
treatment was tested in triplicate in each experiment, which in turn
was carried out about three times. One-way analysis of variance
(one-way ANOVA), followed by Dunnett’s multiple comparison
post test, was used to analyze the difference between treatments.
The concentration–response curves were obtained by the Hill
equation, according to the software instructions. 
Results
Cytotoxicity. Under our experimental conditions, HCA
significantly reduced cell viability although at much higher
concentrations than those of the positive control doxorubicin
(Table I).
Combination assay. The combination of doxorubicin and
HCA significantly reduced cell viability and increased the
cytotoxicity of doxorubicin, as shown by the reversal ratio
analysis (Table I). In particular, for Caco-2 cells, the IC50
value for doxorubicin was statistically reduced by about 3-
and 7-fold in combination with HCA at IC10 (100 μM) and
IC20 (181 μM) concentrations, respectively (Figure 2A,
Table I). Likewise, for CCRF/CEM cells, the cytotoxic
potency of doxorubicin was significantly increased in
combination with HCA: the IC50 value of doxorubicin was
reduced by about 5- and 50-fold in combination with IC10
(50 μM) and IC20 (100 μM) concentrations of HCA (Figure
2B and Table I). Viability of  the resistant CEM/ADR5000
subline was also significantly affected by the combination
(Figure 2C), with an increase of doxorubicin cytotoxicity of
approximately 4- and 8-fold in combination with the IC10
(100 μM) and IC20 (141 μM) concentrations of HCA (Table
I). According to CI, the isobologram analysis highlighted a
synergistic interaction between HCA and doxorubicin for all
the cell lines tested (Figure 3).
Rhodamine 123 efflux assay. In Caco-2 cells, HCA increased
Rho123 fluorescence in a statistically significant and
concentration-dependent manner with respect to the negative
control. At the same concentration of the positive control
verapamil (20 μM), about 35% increase in fluorescence
intensity was found. This highlights that a greater amount of
Rho123 was retained in the cell, likely due to the inhibition
of the efflux pumps by HCA (Figure 4A). Conversely,
Rho123 efflux was not affected by HCA in the CCRF/CEM
cell line (Figure 4B). A fluorescence increase, similar to that
of verapamil, was observed in CEM/ADR5000 cells, thus
suggesting possible P-gp pump inhibition (Figure 4C). 
Discussion
Cinnamaldehyde has been found to possess beneficial
properties for human health, but its clinical application is
limited due to its poor chemical stability and rapid clearance
(6). Therefore, some alkyl-derivatives of cinnamaldehyde
have been developed in order to make the molecule less
reactive and more stable. In the present study, the
semisynthetic derivative HCA was investigated for its
potential chemosensitizing properties in human cancer cells. 
The present results show that HCA itself has a low
cytotoxicity against the cancer cells tested: in contrast,
cinnamaldehyde and its 2'-modified analogs were found to
possess interesting antiproliferative activities (10). From a
structural point of view, these molecules are characterized by
the presence of a propenal in their cinnamal skeleton that forms
a Michael acceptor group (11). A number of compounds
containing a Michael acceptor group have been shown to
ANTICANCER RESEARCH 36: 3347-3352 (2016)
3348
Figure 1. Chemical structure of α-hexylcinnamaldehyde.
possess anticancer activity by interacting with cysteine residues
in different cellular targets: the reactivity of the Michael
acceptor moiety and lipophilicity have been proposed as
structural features for their anticancer properties (12). In the
semi-synthetic derivative HCA, the inclusion of an alkyl chain
at α-β unsaturated double bond reduces the molecule's
reactivity due to the inductive effect of the alkyl group, which
stabilizes the negative charge in the intermediate carbanion.
Accordingly, the presence of an α-hexyl chain in HCA
stabilizes the lead compound structure (13), likely reducing the
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Table I. Quantitation of synergistic, additive, and antagonistic interactions of the combination of α-hexylcinnamaldehyde (HCA) at inhibitory
concentrations (IC)10 and IC20 (μM) with the anticancer drug doxorubicin (DOX) against Caco-2, CCRF/CEM and CEM/ADR5000 cells. For each
experiment, the values for replicates were averaged and the values were expressed as the mean±SEM (n=9).
Caco-2 CCRF/CEM CEM/ADR5000
Drug IC50 (RR) CI r IC50 (RR) CI r IC50 (RR) CI r 
HCA 325.2±1.12 - 0.99 205.7±1.18 - 0.99 274.7±1.10 - 0.99
DOX 5.3±0.50 - 0.99 0.4±0.01 - 0.99 87.7±1.2 - 0.99
DOX + HCA IC10 1.9±0.16* (2.8±0.14) 0.7±0.01 0.97 0.08±0.02* (5.0±0.20) 0.44±0.004 0.95 20.3±0.13* (4.3±0.36) 0.6±0.01 0.97
DOX + HCA IC20 0.8±0.06* (6.5±0.52) 0.7±0.02 0.94 0.008±0.0003* (50.9±1.58) 0.51±0.01 0.97 10.4±0.07* (8.4±0.30) 0.6±0.01 0.97
RR: Reversal ratio, the ratio between the IC50 for DOX alone and DOX plus HCA; CI: combination index: 1, additive effect; <1, synergism; >1,
antagonism; r: correlation coefficient for the regression line, calculated from the median-effect plots according to the basic mass-action principle
(4).*Significantly different from the IC50 for DOX alone (p<0.01; ANOVA + Dunnett’s comparison multiple post test). 
Figure 2. Concentration–response curves for the cytotoxicity of doxorubicin (DOX) alone (black line) and in combination with α-
hexylcinnamaldehyde (HCA) at inhibitory concentrations (IC)10 and IC20 against Caco-2 (A), CCRF/CEM (B) and CEM/ADR5000 (C) cells. Values
are expressed as the mean±SEM (n=9). 
Figure 3. Isobologram analyses of the combination of doxorubicin (DOX) with with α-hexylcinnamaldehyde (HCA) at inhibitory concentrations
(IC)10 (dark gray line) and IC20 (light gray line) against Caco-2 (A), CCRF/CEM (B) and CEM/ADR5000 (C) cells. The IC50 concentrations of DOX
and HCA are plotted on the x and y axes, respectively. The line connecting these two points represents the additive effect; points located below and
above the line indicate a synergistic and antagonistic effect, respectively.
Michael acceptor reactivity and its cytotoxicity. In contrast,
these data suggest a possible role of HCA as a chemosensitizer
when tested in combination with anticancer drugs, particularly
doxorubicin. This compound is a P-gp substrate, hence a
different cytotoxicity profile in our cell lines could be expected
(14). Lacking in ABC transporters, CCRF/CEM cells are
highly sensitive to doxorubicin alone because it is accumulated
in these cells and its cytotoxicity is induced at very low
concentrations. Conversely, in Caco-2 and CEM/ADR500
cells, the expression of ABC transporters (mainly P-gp) reduces
the potency of doxorubicin, hence higher concentrations are
required. Under our experimental conditions, the presence of
HCA increased the potency of doxorubicin similarly in both
CEM/ADR5000 and Caco-2 lines, allowing us to hypothesize
that HCA acts by inhibiting the P-gp pump. However, results
from Rho123 efflux assay suggest that HCA can interfere with
ABC transporter functionality, although not in a pump-specific
manner. Great synergism of HCA and doxorubicin was also
found in CCRF/CEM cells (lacking in ABC transporters): this
suggests that HCA can indirectly inhibit efflux pumps. In this
context, it seems likely that non-specific mechanisms could be
responsible for the reduction of ABC transporter function. In
support of this, compounds containing an α,β-unsaturated
moiety have been reported to modulate MRP1- and MRP2-
mediated transport via direct (chemical interaction) or indirect
(formation of glutathione conjugates which can competitively
inhibit MRP1 and MRP2 or glutathione depletion) mechanisms
(5). Cinnamaldehyde is also known to indirectly inhibit MRP1-
mediated transport by forming glutathione conjugates (5). 
Many MDR-reversing compounds have also been found to
alter membrane fluidity and permeability, thereby modifying
many aspects of transporters, including stability, conformation,
and function: this represents a successful mechanism for
reversing MDR by reducing the efflux of cytotoxic drugs. For
this purpose, HCA has been found to deeply interact with a
biomembrane model of dimyristoylphosphatidyl-choline
multilamellar vesicles, to reduce phospholipid interaction,
thereby altering the membrane properties (15). This alteration
can be potentiated in the presence of other lipophilic
compounds (such as doxorubicin), that can be trapped in
biomembranes and interfere with both phospholipids and
membrane proteins, resulting in a modulation of protein
function (16). Thereafter, the inhibition of the ABC transporter
function by HCA could be due to its ability to block efflux
pumps as a consequence of destabilization of biomembrane
structure.
In conclusion, the present results highlight that HCA
possesses interesting chemosensitizing properties due to
interference with ABC transporter function, possibly as a
consequence of an alteration of membrane permeability, thus
suggesting a possible involvement of non-classical MDR
mechanisms in its chemosensitizing properties.
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